Who is the current CEO of Amgen Inc.?

The current CEO of Amgen Inc. is Robert A. Bradway, who has served since undefined.

Who was the first CEO of Amgen Inc.?

Robert A. Bradway was among the earliest leaders of Amgen Inc., serving from undefined.

How many CEOs has Amgen Inc. had?

Amgen Inc. has had 4 documented leaders in its history.

CorpDigest

Search brand historiesSearchK Contact

Amgen Inc.

Biotechnology / BiopharmaceuticalsFounded 1980- Updated July 2025

Reviewed by Swet Parvadiya

Last reviewed: July 2025

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.

CorpDigest

Search brand historiesSearchK Contact

Amgen Inc.

Biotechnology / BiopharmaceuticalsFounded 1980- Updated July 2025

Reviewed by Swet Parvadiya

Last reviewed: July 2025

Leadership History

Amgen Inc.: CEO History

4 leaders · Full leadership timeline

Last reviewed: 2025-07-15 · By Swet Parvadiya

Company Overview

Amgen Inc. is a Biotechnology / Biopharmaceuticals company with $33.4B in 2024 revenue and 24K employees worldwide. Amgen Inc. Was established at the dawn of the biotechnology era and has grown to become the archetype of what a successful independent biotech company can achieve. Operating from its sprawling campus in Thousand Oaks, California — a city that barely existed when Amgen moved there in 1981 and has since grown significantly in part because of Amgen's presence — the company employs approximately 24,000 people globally and maintains research, development, and manufacturing operations across the United States, Europe, and Asia-Pacific. The company is organized into research and development divisions focused on oncology, cardiovascular and metabolic diseases, inflammation, bone health, rare diseases, and neuroscience. Its commercial organization operates separate U.S. And international business units, with the U.S. Segment accounting for approximately 75% of product revenues in 2024. Amgen's manufacturing organization is among the most sophisticated in the biopharma industry, running validated large-scale biologic production at facilities in Thousand Oaks, California; West Greenwich, Rhode Island; Juncos, Puerto Rico; Breda, Netherlands; and Singapore. Amgen trades on the Nasdaq Stock Market under the ticker symbol AMGN and has been a component of the Dow Jones Industrial Average since 2020, when it replaced Pfizer in the index — a symbolic recognition of the biotech industry's ascent to the center of American commercial healthcare. With a market capitalization of approximately $153 billion and a dividend yield of approximately 3%, Amgen occupies a unique position as both a growth story and an income investment within the healthcare sector.

Robert A. Bradway

Chairman and Chief Executive Officer

Legacy

Robert Bradway became Amgen's CEO in May 2012, succeeding Kevin Sharer, and has overseen the company's most significant strategic transformation since the Immunex acquisition in 2002. Under Bradway's leadership, Amgen completed five major acquisitions totaling approximately $60 billion, including the Horizon deal, and built a biosimilars business from scratch. He has maintained Amgen's dividend growth track record while managing the company through patent expirations affecting its legacy EPO and Neulasta franchises, demonstrating the financial discipline and portfolio management skills required of a CEO overseeing a company with significant product life-cycle challenges. Bradway's most consequential near-term bet is the obesity drug MariTide, a program he has publicly championed despite investor skepticism about Amgen's ability to compete against Eli Lilly and Novo Nordisk.

Peter H. Griffith

Executive Vice President and Chief Financial Officer

Legacy

Peter Griffith joined Amgen as CFO in 2019, bringing experience from roles at KPMG and board positions at multiple public companies. His most consequential challenge has been managing Amgen's capital structure through the $27.8 billion Horizon acquisition, navigating interest rate environments significantly higher than when the deal was originally conceived and communicating a credible deleveraging plan to bond and equity investors simultaneously. Griffith has been central to Amgen's investor relations narrative around the gap between GAAP and non-GAAP earnings metrics — a communication challenge particularly acute for acquisitive pharmaceutical companies where amortization of intangible assets can represent billions of dollars of GAAP charges annually. Under his financial stewardship, Amgen has maintained its investment-grade credit ratings and dividend growth trajectory despite elevated debt.

David M. Reese, M.D.

Executive Vice President of Research and Development

Legacy

David Reese oversees Amgen's approximately $4.8 billion annual R&D organization spanning discovery research, clinical development, regulatory affairs, and medical affairs. He has been the architect of Amgen's pipeline strategy for the obesity program including MariTide, the DLL3-targeting oncology program including tarlatamab, and the lipoprotein(a)-targeting cardiovascular program including olpasiran. Reese has consistently emphasized Amgen's differentiated focus on first-in-class or best-in-class biology over fast-follower molecules, a strategy that has produced genuine clinical breakthroughs in oncology and cardiovascular medicine but also contributed to higher R&D spending per approved drug than some more opportunistic pipeline strategies.

Murdo Gordon

Executive Vice President of Global Commercial Operations

Legacy

Murdo Gordon leads Amgen's global commercial organization, responsible for the sales, marketing, and market access functions across all marketed products in the U.S. And internationally. He has been central to managing the complex formulary negotiation dynamics with pharmacy benefit managers across Amgen's broad portfolio, including the competitive trade-offs required to maintain access for newer products like Repatha and Otezla while protecting revenue for established products facing competitive and biosimilar pressure. Gordon's international commercial expansion strategy, particularly in China where Amgen has invested heavily in building a direct sales force for products including Repatha and Prolia, represents a multi-year growth initiative that is beginning to contribute meaningful incremental revenue.

Challenges & Strategic Context

Amgen faces a convergence of structural, regulatory, and competitive pressures that are arguably more acute in 2025 than at any prior point in its history. The most immediate financial challenge is the $27.8 billion debt load inherited from the Horizon Therapeutics acquisition. With long-term debt of approximately $58 billion at the end of fiscal year 2024, Amgen carries interest expense that materially compresses net income. The company paid approximately $2.5 billion in interest during 2024, and while Bradway's management team has committed to aggressive debt reduction, the company must navigate this deleveraging process while simultaneously funding a $4.8 billion annual R&D program and maintaining its dividend — a trilemma that limits financial flexibility.

Patent cliff risk represents an existential concern for the medium term. Prolia and XGEVA, both using the denosumab molecule and collectively generating over $4.8 billion in 2024 revenues, face biosimilar competition beginning around 2025 to 2026 as key patents expire. Enbrel, which generates approximately $3.6 billion annually in the U.S., has already seen market erosion from competing inflammation biologics including Humira, Stelara, and emerging IL-23 inhibitors. Repatha faces competitive pressure from Novartis's inclisiran and evolving treatment guidelines. The question of how much revenue Amgen can sustain through the mid-2020s patent cliff cycle while simultaneously growing new franchises defines the company's near-term financial trajectory.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.

Leadership History

Amgen Inc.: CEO History

4 leaders · Full leadership timeline

Last reviewed: 2025-07-15 · By Swet Parvadiya

Company Overview

Robert A. Bradway

Chairman and Chief Executive Officer

Legacy

Peter H. Griffith

Executive Vice President and Chief Financial Officer

Legacy

David M. Reese, M.D.

Executive Vice President of Research and Development

Legacy

Murdo Gordon

Executive Vice President of Global Commercial Operations